| Literature DB >> 26963719 |
Chien-Yuan Huang1,2,3, Cheng-Long Wu1,4,5, Jin-Shang Wu6, Jung-Wei Chang6, Ya-Yun Cheng1, Yau-Chang Kuo4,5, Yi-Ching Yang6, Ching-Chang Lee1,7, How-Ran Guo1,4,5,7,8.
Abstract
BACKGROUND: Dioxin is an industrial pollutant related to various diseases, but epidemiological data on its effects on the kidney are limited. Therefore, we conducted a study to evaluate the association between dioxin exposure and chronic kidney disease (CKD) and identify the related factors.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26963719 PMCID: PMC4786121 DOI: 10.1371/journal.pone.0150248
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Distributions (number and percentage) of variables in the participants and comparisons of variables between participants with and without a high level of dioxin.
| Total | PCDD/Fs (pg WHO98-TEQDF/g lipid) | |||
|---|---|---|---|---|
| Variables | < 20 | ≥ 20 | p | |
| N (%) | N (%) | N (%) | ||
| Gender | < 0.001 | |||
| Men | 1546 (53.3) | 870 (56.3) | 676 (43.7) | |
| Women | 1352 (46.7) | 601 (44.5) | 751 (55.5) | |
| Age (year) | < 0.001 | |||
| < 40 | 1124 (38.8) | 972 (86.5) | 152 (13.5) | |
| 40–64 | 1188 (41.0) | 429 (36.1) | 759 (63.9) | |
| ≥ 65 | 586 (20.2) | 70 (11.9) | 516 (88.1) | |
| Metabolic syndrome | < 0.001 | |||
| No | 1973 (71.5) | 1179 (59.8) | 794 (40.2) | |
| Yes | 785 (28.5) | 273 (34.8) | 512 (65.2) | |
| Diabetes mellitus | < 0.001 | |||
| No | 2472 (85.3) | 1384 (56.0) | 1088 (44.0) | |
| Yes | 426 (14.7) | 88 (20.2) | 339 (79.8) | |
| Hypertension | <0.001 | |||
| No | 2411 (83.3) | 1373 (56.9) | 1038 (43.1) | |
| Yes | 485 (16.7) | 96 (19.8) | 389 (80.2) | |
| Insulin (mU/L) | 0.003 | |||
| < 22.0 | 2579 (93.3) | 1375 (53.3) | 1204 (46.7) | |
| ≥ 22.0 | 186 (6.7) | 78 (41.9) | 108 (58.1) | |
| Uric acid (mg/dL) | 0.025 | |||
| ≤ 7 | 2276 (78.5) | 1180 (51.8) | 1096 (48.2) | |
| > 7 | 622 (21.5) | 291 (46.8) | 331 (53.2) | |
| Chronic kidney disease | < 0.001 | |||
| No | 2718 (93.8) | 1447 (53.2) | 1271 (46.8) | |
| Yes | 180 (6.2) | 24 (13.3) | 156 (86.7) | |
| Mercury (ppb) | <0.001 | |||
| ≤ 20 | 2687 (92.7) | 1416 (52.7) | 1271 (47.3) | |
| > 20 | 211 (7.3) | 55 (26.1) | 156 (73.9) | |
adefined as meeting three of the following criteria: fasting glucose ≥ 100 mg/dL or under diabetes medication, waist circumference ≥ 90 cm in men or ≥ 80cm in women, triglycerides ≥ 150 mg/dL or under drug treatment for elevated triglycerides, high-density lipoprotein (HDL) < 40 mg/dL in men or < 50 mg/dL in women, and blood pressures ≥ 130/85 mmHg or under antihypertensive medication; data not available on 140 participants without high exposure
bdefined as fasting glucose > 126 mg/dL or under diabetes medication
cdefined as having an estimated glomerular filtration rate ≤ 60 mL/min/1.73m2, an e-GFR > 60 ml/min/1.73m2 with proteinuria, or a previous diagnosis of chronic kidney disease by a physician
dcolumn percentage
efor chi-square test
Means and standard errors (SEs) of variables according to quartiles of PCDD/Fs.
| Variables | Quartiles of PCDD/Fs | ||||
|---|---|---|---|---|---|
| Mean (SE) | Q1 | Q2 | Q3 | Q4 | p |
| Mercury (ppb) | 7.14 (0.17) | 9.76 (0.25) | 11.83 (0.32) | 12.05 (0.32) | <0.001 |
| Age (year) | 31.02 (0.38) | 41.90 (0.51) | 53.78 (0.54) | 62.16 (0.52) | <0.001 |
| Fasting glucose (mg/dL) | 91.25 (0.69) | 96.72 (1.23) | 106.39 (1.50) | 110.90 (1.52) | <0.001 |
| Insulin (mU/L) | 8.70 (0.35) | 8.16 (0.34) | 9.75 (0.40) | 11.27 (0.77) | <0.001 |
| Uric acid (mg/dL) | 5.75 (0.06) | 5.78 (0.09) | 5.90 (0.06) | 5.93 (0.09) | 0.210 |
| eGFR (mL/min/1.73m2) | 109.08 (0.91) | 102.07 (0.97) | 91.91 (0.93) | 87.71 (1.13) | <0.001 |
athe cut-offs are 11.30, 19.60, and 35.33 pg WHO98-TEQDF/g lipid
bfor ANOVA
Comparisons between participants with and without chronic kidney disease (CKD).
| Without CKD | With CKD | p | |
|---|---|---|---|
| N (%) | N (%) | ||
| PCDD/Fs (pg WHO98-TEQDF/g lipid) | < 0.001 | ||
| < 20 | 1447 (98.4) | 24 (1.6) | |
| ≥ 20 | 1271 (89.1) | 156 (10.9) | |
| Gender | 0.044 | ||
| Men | 1463 (94.6) | 83 (5.4) | |
| Women | 1255 (92.8) | 97 (7.2) | |
| Age (year) | |||
| < 40 | 1118 (99.5) | 6 (0.5) | < 0.001 |
| 40–64 | 1143 (96.2) | 45 (3.8) | |
| ≥ 65 | 457 (78.0) | 129 (22.0) | |
| Mercury (ppb) | 0.743 | ||
| ≤ 20 | 2519 (93.7) | 168 (6.3) | |
| > 20 | 199 (94.3) | 12 (5.7) | |
| Metabolic syndrome | < 0.001 | ||
| No | 1891 (95.8) | 82 (4.2) | |
| Yes | 695 (88.5) | 90 (11.5) | |
| Diabetes mellitus | < 0.001 | ||
| No | 2355 (95.3) | 117 (4.7) | |
| Yes | 362 (85.2) | 63 (14.8) | |
| Hypertension | <0.001 | ||
| No | 2323 (96.4) | 88 (3.6) | |
| Yes | 393 (81.0) | 92 (19.0) | |
| Insulin (mU/L) | <0.001 | ||
| < 22.0 | 2430 (94.2) | 149 (5.8) | |
| ≥ 22.0 | 162 (87.1) | 24 (12.9) | |
| Uric acid (mg/dL) | < 0.001 | ||
| ≤ 7 | 2178 (95.7) | 98 (4.3) | |
| > 7 | 540 (86.8) | 82 (13.2) |
adefined as meeting three of the following criteria: fasting glucose ≥ 100 mg/dL or under diabetes medication, waist circumference ≥ 90 cm in men or ≥ 80 cm in women, triglycerides ≥ 150 mg/dL or under drug treatment for elevated triglycerides, high-density lipoprotein (HDL) < 40 mg/dL in men or < 50 mg/dL in women, and blood pressures ≥ 130/85 mmHg or under antihypertensive medication; data not available on 140 participants without high dioxin levels.
bdefined as fasting glucose > 126 mg/dL or under diabetes medication
cthe prevalence of CKD in participants with the variable
dfor chi-square test
Risk factors and associated odds ratios for chronic kidney disease among the participants.
| Variables | Uni-variate Analyses | Multi-variate Analyses | |
|---|---|---|---|
| OR (95% CI) | AOR | AOR | |
| PCDD/Fs (pg WHO98-TEQDF/g lipid) | |||
| < 20 | 1 | 1 | 1 |
| ≥ 20 | 7.40 (4.78–11.45) | 1.74 (1.02–2.97) | 1.76 (1.04–2.99) |
| Gender | |||
| Men | 1 | 1 | 1 |
| Women | 1.36 (1.01–1.84) | 1.74 (1.19–2.54) | 1.74 (1.20–2.53) |
| Mercury (ppb) | |||
| ≤ 20 | 1 | 1 | |
| > 20 | 0.90 (0.50–1.65) | 0.69 (0.34–1.41) | |
| Metabolic syndrome | |||
| No | 1 | 1 | |
| Yes | 2.99 (2.19–4.08) | 1.01 (0.69–1.49) | |
| Diabetes mellitus | |||
| No | 1 | 1 | |
| Yes | 3.50 (2.53–4.85) | 1.24 (0.82–1.87) | |
| Hypertension | |||
| No | 1 | 1 | 1 |
| Yes | 6.18 (4.53–8.44) | 1.62 (1.11–2.37) | 1.68 (1.17–2.42) |
| Insulin (mU/L) | |||
| < 22.0 | 1 | 1 | 1 |
| ≥ 22.0 | 2.42 (1.53–3.83) | 2.04 (1.19–3.49) | 2.14 (1.26–3.61) |
| Uric acid (mg/dL) | |||
| ≤ 7 | 1 | 1 | 1 |
| > 7 | 3.38 (2.48–4.59) | 4.38 (2.99–6.40) | 4.25 (2.92–6.20) |
| Age (year) | |||
| < 40 | 1 | 1 | 1 |
| 40–64 | 7.34 (3.12–17.26) | 4.70 (1.88–11.73) | 4.66 (1.87–11.62) |
| ≥ 65 | 52.60 (23.03–120.11) | 25.67 (10.09–65.32) | 26.66 (10.51–67.62) |
aOR: odds ratio; CI: confidence interval
bAOR: adjusted odds ratio, the full model included PCDD/Fs, gender, mercury, metabolic syndrome, age, fasting glucose, insulin, and uric acid
cAOR:adjusted odds ratio, the final model included PCDD/Fs, insulin, uric acid, and age
ddefined as meeting three of the following criteria: fasting glucose ≥ 100 mg/dL or under diabetes medication, waist circumference ≥ 90 cm in men or ≥ 80 cm in women, triglycerides > 150 mg/dL or under drug treatment for elevated triglycerides, high-density lipoprotein (HDL) < 40 mg/dL in men or < 50 mg/dL in women, and blood pressures ≥ 130/85 mmHg or under antihypertensive medication; data not available on 140 participants without high dioxin levels
edefined as fasting glucose > 126 mg/dL or under diabetes mellitus medication
*p< 0.05 for Wald test